Should You Continue to Retain ABT Stock in Your Portfolio Now?
ZacksAbbott’s robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
Abbott’s robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.